GlassScriptPhysician profile
Silas Money
NPI 1487221651
$9,254.84
in general payments reported to CMS, 2019-2025
23 companies · $2,257 in 2025
The $2,257 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $886 · 2023: $2,952 · 2024: $3,159 · 2025: $2,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,856 · Education: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,856.30 |
| Education | $512.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,037.04 | 2022-2025 | |
| Janssen Biotech, INC. | $1,025.91 | 2022-2025 | Tremfya, Stelara |
| Novartis Pharmaceuticals Corporation | $981.51 | 2022-2025 | |
| Lilly USA, LLC | $697.23 | 2022-2025 | Taltz, Ebglyss, Zepbound |
| Regeneron Healthcare Solutions, INC. | $670.21 | 2023-2025 | Dupixent, Libtayo |
| Ucb, INC. | $575.93 | 2022-2024 | Bimzelx, Cimzia |
| Amgen INC. | $553.84 | 2022-2025 | Otezla, Otezla |
| Genzyme Corporation | $546.35 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $485.59 | 2024-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.86 | 2022-2025 | Spevigo |
| Incyte Corporation | $368.71 | 2024-2025 | Opzelura |
| Pfizer INC. | $350.46 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $315.80 | 2023-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $282.18 | 2022-2025 | Ilumya |
| Almirall LLC | $240.49 | 2023 | Klisyri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $238.87 | 2023-2025 | Siliq, Arazlo, Jublia |
| Dermavant Sciences, INC. | $170.81 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $153.95 | 2024-2025 | Nemluvio |
| Stemline Therapeutics INC. | $34.77 | 2023 | Elzonris |
| Organogenesis INC. | $33.61 | 2025 | Novachor |
| Helsinn Therapeutics (U.S.), INC. | $29.74 | 2022-2024 | Valchlor |
| Mallinckrodt Hospital Products INC. | $28.22 | 2023 | Uvadex |
| Leo Pharma INC. | $20.76 | 2025 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silas Money listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.